Quidel Q2 Revenues Up 6 Percent
NEW YORK (GenomeWeb) — Quidel said after the close of the market Tuesday that second quarter revenues rose 6 percent to $31.5 million compared to $29.7 million in the second quarter of 2013.
Packaging isothermal PCR reagents in blisters and using lateral flow detection, researchers at Boston University hope to develop a low-cost, disposable assay for Bordetella pertussis, the causative agent of whooping cough.
Quidel disclosed yesterday that it has acquired AnDiaTec, a German molecular diagnostics company, for approximately $2.6 million upfront and a three-year, $4.7 million R&D earn-out.
With its acquisition this week of privately held molecular diagnostic developer BioHelix, clinical diagnostics firm Quidel adds to its portfolio of technologies to enable its burgeoning molecular diagnostics business.
Quidel Acquires BioHelix for $10M Plus Milestones
NEW YORK (GenomeWeb News) – Clinical diagnostics firm Quidel said today that it has acquired BioHelix.
Mar 29, 2012
Mar 8, 2012
Oct 20, 2011
Oct 17, 2011
FDA Clears BioHelix Herpes Simplex Virus Assay
Oct 13, 2011
Oct 6, 2009